Acquisition of DIPSS-Plus variables, except unfavorable cytogenetics and age >65 years, at the latest available follow-up in study patients
| Variables . | N= . | Pre-PMF, n (%) . | Overt PMF, n (%) . | P . |
|---|---|---|---|---|
| Hemoglobin, <100 g/L | 482 | 54 (23.1) | 110 (44.4) | <.0001 |
| Leukocytes, >25 × 109/L | 587 | 35 (14.3) | 77 (22.4) | .009 |
| Platelets, <100 × 109/L | 558 | 37 (14.9) | 76 (24.6) | .006 |
| Circulating blasts, ≥1% | 525 | 56 (23.4) | 117 (40.9) | <.0001 |
| Constitutional symptoms | 334 | 21 (14.6) | 42 (22.1) | .049 |
| Transfusion dependency | 617 | 52 (20.2) | 139 (38.6) | <.0001 |
| DIPSS | 658 | |||
| Low | 79 (28.6) | 26 (6.8) | <.0001 | |
| Intermediate-1 | 102 (37.0) | 91 (23.8) | ||
| Intermediate-2 | 67 (24.3) | 179 (46.9) | ||
| High | 28 (10.1) | 86 (22.5) |
| Variables . | N= . | Pre-PMF, n (%) . | Overt PMF, n (%) . | P . |
|---|---|---|---|---|
| Hemoglobin, <100 g/L | 482 | 54 (23.1) | 110 (44.4) | <.0001 |
| Leukocytes, >25 × 109/L | 587 | 35 (14.3) | 77 (22.4) | .009 |
| Platelets, <100 × 109/L | 558 | 37 (14.9) | 76 (24.6) | .006 |
| Circulating blasts, ≥1% | 525 | 56 (23.4) | 117 (40.9) | <.0001 |
| Constitutional symptoms | 334 | 21 (14.6) | 42 (22.1) | .049 |
| Transfusion dependency | 617 | 52 (20.2) | 139 (38.6) | <.0001 |
| DIPSS | 658 | |||
| Low | 79 (28.6) | 26 (6.8) | <.0001 | |
| Intermediate-1 | 102 (37.0) | 91 (23.8) | ||
| Intermediate-2 | 67 (24.3) | 179 (46.9) | ||
| High | 28 (10.1) | 86 (22.5) |
The number (N=) of patients evaluated for each variable at the latest follow-up is shown. Becoming older than 65 y was not considered as an adverse variable for the purposes of this analysis. A few patients only had cytogenetic information at latest follow-up, therefore acquisition of adverse cytogenetics was also not included in this analysis.